Favorable legislation and recent commercial successes have stimulated growing interest in the discovery of novel orphan drugs. However, there are many strategic considerations that are peculiar to the R&D process for diseases of low prevalence.
Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions